CIA
AMPH icon

Capital Impact Advisors’s Amphastar Pharmaceuticals AMPH Stock Holding History

Capital Impact Advisors’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-16,425
Closed -$657K – 3
2024
Q2 		$657K Hold
16,425
– – 1.85% 27
2024
Q1 		$721K Buy
16,425
+1,121
+7% +$57.9K 0.94% 43
2023
Q4 		$947K Hold
15,304
– – 1.24% 30
2023
Q3 		$704K Hold
15,304
– – 1.18% 34
2023
Q2 		$880K Hold
15,304
– – 0.97% 18
2023
Q1 		$574K Buy
15,304
+635
+4% +$20.8K 0.7% 55
2022
Q4 		$411K Hold
14,669
– – 0.4% 106
2022
Q3 		$416K Buy
14,669
+834
+6% +$27.2K 0.41% 99
2022
Q2 		$481K Sell
13,835
-3,925
-22% -$140K 0.44% 100
2022
Q1 		$638K Buy
+17,760
New +$504K 0.46% 107

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Impact Advisors's AMPH Position: Q3 2024 in Review

Capital Impact Advisors sold out of Amphastar Pharmaceuticals (AMPH) in Q3 2024, closing a stake of 16,425 shares — an estimated $657K sold.

Capital Impact Advisors first reported a position in AMPH in Q1 2022 and held it in 10 quarters. The position peaked at $947K in Q4 2023. 279 funds tracked by Wall St. Rank hold AMPH as of Q3 2024.

  • Capital Impact Advisors reported no remaining Amphastar Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Capital Impact Advisors sold 16,425 Amphastar Pharmaceuticals shares in Q3 2024, an estimated $657K.
  • Capital Impact Advisors first reported a position in Amphastar Pharmaceuticals in Q1 2022 and held it in 10 quarters.
  • Capital Impact Advisors's Amphastar Pharmaceuticals position peaked at $947K in Q4 2023.
  • 279 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q3 2024.

Based on Capital Impact Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.